Alar Pharmaceuticals (ROCO:6785) Short Ratio

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6785 Alar Pharmaceuticals Inc ROCO:6785
51 GF Score
Price NT$98.60
GF Value NT$96.84
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Alar Pharmaceuticals Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

ROCO:6785
51GF Score
Alar Pharmaceuticals Inc ROCO:6785
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Alar Pharmaceuticals (ROCO:6785) Overvalued in 2026?

Based on GuruFocus' analysis, Alar Pharmaceuticals stock appears to be overvalued. The current stock price of NT$98.60 is trading 1.8% above its estimated GF Value™ of NT$96.84. GuruFocus considers Alar Pharmaceuticals to be Fairly Valued.

Key valuation signals for ROCO:6785:

  • Short Ratio:
  • GF Value™: NT$96.84 vs. price of NT$98.60 (1.8% above fair value)
  • GF Score™: 51/100 with 2 warning signs

No single metric tells the full story. See the ROCO:6785 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Alar Pharmaceuticals Business Description

Address Jhongke Road, No. 32, No. 2, 5th Floor, Situn District, Taichung, TWN, 428015
Alar Pharmaceuticals Inc is a drug development company mainly engaged in the research and development of new drugs, sales of western pharmaceuticals, and medical devices. It focuses on developing long-acting release drug products for CNS disorders and chronic diseases, which mainly include opioid use disorder, chronic pain, and depressive disorder. The company currently has only a new drug development division, and its product pipeline comprises various drug candidates such as ALA-1000 (Buprenorphine), ALA-1300, ALA-2000 (Naltrexone), ALA-3000 (Ketamine), ALA-4000 (Apomorphine), and ALA-5000 (Third-generation antipsychotic). Geographically, the company generates maximum revenue from the USA and also has its presence in Taiwan and the United Kingdom.
51GF Score

Get the complete analysis for ROCO:6785

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$98.60
Price
NT$96.84
GF Value